IMPLEMENTATION OF THE DENGUE “SCREEN AND VACCINATE” STRATEGY
A toolkit for country decision makers, program planners and local implementers Based on results of long-term clinical trial data confirming differences in dengue vaccine performance based on prior dengue infection, Sanofi Pasteur proposed an update label for...
TECHNICAL SUPPORT TO DENGUE VACCINE IMPLEMENTATION: INFORMATION FOR DECISION-MAKING
Since December 2015, dengue is a vaccine-preventable disease. What are the key factors to consider for vaccine introduction. The CYD-TDV vaccine (commercial name Dengvaxia®) is a dengue tetravalent vaccine (live attenuated), that has been licensed for the prevention...
EXPERT MEETING ON RAPID DIAGNOSTIC TESTS AND IMPLEMENTATION STRATEGIES FOR THE DENGUE VACCINE
Brainstorming on dengue vaccination with CYD-TDV (Dengvaxia®). In January 2019, the Partnership for Dengue Control (PDC) and the Global Dengue and Aedes-transmitted diseases Consortium (GDAC) organized a 3-day experts’ workshop hosted by the Mérieux Foundation at Les...